U.S. stock markets opened slightly lower on Wednesday, with futures on the Nasdaq 100 (US100) and S&P 500 slipping into negative territory. Investors appear to be treading cautiously as they await a series of key economic releases that could shape the near-term direction of the markets. One of the early highlights will be the weekly crude oil inventory report, which could provide insight into the health of the energy sector and broader commodity market trends.
However, the focal point of the day will be the release of the FOMC meeting minutes later this evening. This document could offer important clues about the Federal Reserve’s monetary policy outlook and significantly influence investor sentiment across both equity and bond markets.
Looking ahead, markets are also gearing up for Thursday’s PMI data releases, which will give an updated snapshot of activity in the U.S. manufacturing and services sectors. These figures are widely watched as indicators of economic momentum and may play a crucial role in shaping expectations for future growth.
US100 (H1 interval)
Nasdaq-100 futures (US100) are trading slightly lower ahead of the U.S. session open. Following a sharp downturn in recent sessions, the index has entered a consolidation phase near the 23,400 level, signaling a temporary pause in selling pressure. On the hourly chart, price action remains range-bound, with prices hovering around the short-term exponential moving averages – a clear sign that the market lacks a decisive direction at this stage. Traders appear to be waiting on upcoming macroeconomic releases, which are likely to provide the next catalyst. The market’s reaction to these data points will be key in determining whether this consolidation evolves into further declines or sets the stage for a potential rebound.
Source: xStation5
Company Updates:
-
La-Z-Boy (LZB.US): Shares are down 13% after the company released weaker-than-expected earnings and lowered guidance for the upcoming fiscal quarter. A sharp decline in operating margins was reported, with EPS at $0.47, missing the $0.53 consensus. Management pointed to a challenging macro backdrop and rising cost pressures.
-
Celldex Therapeutics (CLDX.US): The stock is trading 5% lower after mixed results from a Phase II trial of its drug barzolvolimab. While the trial met biological endpoints (mast cell reduction), it failed to demonstrate clinical improvement in EoE patients. The company has decided to halt development of the drug for this indication but remains committed to other therapeutic areas.
-
Novavax (NVAX.US): Shares are down 7% after Bank of America Global Research downgraded the stock from “neutral” to “underperform.” Analysts flagged competitive pressures and uncertainty around the company’s position in the COVID-19 and broader vaccine market as major concerns.
Daily Summary: Powell pulls markets back up! 📈 EURUSD higher
EURUSD higher after Powell's speech! 💶📈
Salesforce announces partnerships with OpenAI and Anthropic🚨
Intel down 5% 📉
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
